First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors

Local Institution - 0060, Río Cuarto

Local Institution - 0017, Lausanne

Local Institution - 0059, Buenos Aires

Local Institution - 0042, Ciudad Autónoma de Buenos Aires

Local Institution - 0006, Wollstonecraft

Local Institution - 0026, Northmead

Local Institution - 0047, Villa Siburu

Local Institution - 0049, Murdoch

Local Institution - 0031, Zurich

Local Institution - 0039, Ghent

Local Institution - 0001, New York

Local Institution - 0007, New York

Local Institution - 0015, Monroeville

Local Institution - 0004, Philadelphia

Local Institution - 0061, Rozzano

Local Institution - 0056, Madrid

Local Institution - 0055, Madrid

Local Institution - 0013, Madrid

Local Institution - 0054, Málaga

Local Institution - 0058, Atlanta

Local Institution - 0012, Pamplona

Local Institution - 0020, Toulouse

Local Institution - 0030, Essen

Local Institution - 0008, Ramat Gan

Local Institution - 0010, Siena

Local Institution - 0033, Sioux Falls

Local Institution - 0019, Lyon

Local Institution - 0011, Napoli

Local Institution - 0018, Villejuif

Local Institution - 0035, Craiova

Local Institution - 0034, Cluj-Napoca

Local Institution - 0052, Viña del Mar

Local Institution - 0029, Haifa

Local Institution - 0048, Santiago

Local Institution - 0041, Santiago

Local Institution - 0025, Boston

Local Institution - 0002, Hackensack

Local Institution - 0028, New Brunswick

Local Institution - 0053, ABB

Local Institution - 0057, CABA

Local Institution - 0062, Córdoba

Local Institution - 0037, Edmonton

Local Institution - 0023, Vancouver

Local Institution - 0027, Ottawa

Local Institution - 0022, Toronto

Local Institution - 0045, Helsinki

Local Institution - 0009, Dresden

Local Institution - 0038, Amsterdam

Local Institution - 0043, Nijmegen

Local Institution - 0040, Oslo

Local Institution - 0036, Warsaw

Local Institution - 0014, Barcelona